Standard & Poor’s Global Ratings last week said it believes that recent payment cuts to not-for-profit hospitals under the 340B drug savings program “will likely weaken their operating performance at a time of already tightening margins.” The report notes that the cuts “could lead to negative rating actions if hospital-specific funding reductions were material and not offset by other management actions. And despite the possibility of a legal challenge to the cuts, additional proposed program reforms at the federal level could further negatively affect these providers' finances.” A federal appeals court earlier this month heard oral arguments in a case brought by the AHA, Association of American Medical Colleges, America’s Essential Hospitals and three hospital organizations to challenge a nearly 30% reduction to Medicare payments for 340B drugs. The AHA hopes for a ruling from the court sometime this summer.

Headline
The AHA, the New Hampshire Hospital Association and 340B Health have filed an amicus brief supporting Mary Hitchcock Memorial Hospital’s request for a…
Headline
The Department of Health and Human Services’ Health Resources and Services Administration Oct. 1 announced approval of 10 drug companies to participate in the…
Headline
The Centers for Medicare & Medicaid Services’ 340B Part D claims data repository became available Oct. 1 for voluntary data submissions. While data…
Headline
The AHA Sept. 23 submitted comments on the Strengthening the Exercise of Controls and Upgrading Requirements for Efficiency in 340B Act (SECURE 340B Act). The…
Headline
As policymakers continue to discuss healthcare legislation, the AHA has developed several new resources to help hospitals and other stakeholders understand the…
Headline
The Centers for Medicare & Medicaid Services has released a fact sheet and FAQs on the 340B Part D claims data repository that will go live Oct. 1. Data…